Receipt of Serial Endoscopy Procedures Prior to Esophageal Adenocarcinoma Diagnosis Is Associated with Better Survival

Cummings, Linda C.; Kou, Tzuyung D.; Chak, Amitabh; Schluchter, Mark D.; Margevicius, Seunghee; Cooper, Gregory S.

doi:10.1007/s10620-021-06927-1

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Role Of Surveillance In Management Of Ndbementioning

confidence: 93%

“…In another cohort study of 5532 patients based on the Surveillance, Epidemiology and End-Results Medicare database, serial surveillance endoscopy was associated with EAC being diagnosed in a localized stage (OR: 2.95; 95% CI: 2.07–4.19). 16 Even when adjusting for lead-time and length-time bias, improved survival rate was noted in patients who received serial endoscopies (HR: 0.45; 95% CI: 0.37–0.55). The reasons for these disparate results are many: (1) most of these are retrospective cohort studies or are based on administrative claims data; (2) they may not have adequately addressed lead-time and length-time bias; (3) they have excluded younger populations with aggressive tumors who are already dead; and (4) lack of standardized surveillance biopsy protocols and inferior optical resolution for identifying abnormal areas of mucosa in the older studies.…”

Section: Role Of Surveillance In Management Of Ndbementioning

confidence: 95%

See 1 more Smart Citation

Management of nondysplastic Barrett’s esophagus: When to survey? When to ablate?

Puthenpura

Sanaka

Qin

et al. 2022

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Barrett’s esophagus (BE), a precursor for esophageal adenocarcinoma (EAC), is defined as salmon-colored mucosa extending more than 1 cm proximal to the gastroesophageal junction with histological evidence of intestinal metaplasia. The actual risk of EAC in nondysplastic Barrett’s esophagus (NDBE) is low with an annual incidence of 0.3%. The mainstay in the management of NDBE is control of gastroesophageal reflux disease (GERD) along with enrollment in surveillance programs. The current recommendation for surveillance is four-quadrant biopsies every 2 cm (or 1 cm in known or suspected dysplasia) followed by biopsy of mucosal irregularity (nodules, ulcers, or other visible lesions) performed at 3- to 5-year intervals. Challenges to surveillance include missed cancers, suboptimal adherence to surveillance guidelines, and lack of strong evidence for efficacy. There is minimal role for endoscopic eradication therapy in NDBE. The role for enhanced imaging techniques, artificial intelligence, and risk prediction models using clinical data and molecular markers is evolving.

show abstract

Section: Role Of Surveillance In Management Of Ndbementioning

confidence: 93%

Section: Role Of Surveillance In Management Of Ndbementioning

confidence: 95%

Management of nondysplastic Barrett’s esophagus: When to survey? When to ablate?

Puthenpura

Sanaka

Qin

et al. 2022

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…However, endoscopic resection still has limitations and is more commonly used as a diagnostic method than a treatment. A retrospective cohort study demonstrated that, compared to patients who did not undergo continuous endoscopic examination, patients who underwent continuous endoscopy before the diagnosis of EAC were associated with less advanced locoregional staging, better prognosis and survival[ 9 ].…”

Section: Endoscopic Resection: Growing In Importancementioning

confidence: 99%

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction

Zheng¹,

Zhao²

2022

WJG

View full text Add to dashboard Cite

Esophageal adenocarcinoma (EAC) and adenocarcinoma of the esophagogastric junction (EGJA) have long been associated with poor prognosis. With changes in the spectrum of the disease caused by economic development and demographic changes, the incidence of EAC and EGJA continues to increase, making them worthy of more attention from clinicians. For a long time, surgery has been the mainstay treatment for EAC and EGJA. With advanced techniques, endoscopic therapy, radiotherapy, chemotherapy, and other treatment methods have been developed, providing additional treatment options for patients with EAC and EGJA. In recent decades, the emergence of multidisciplinary therapy (MDT) has enabled the comprehensive treatment of tumors and made the treatment more flexible and diversified, which is conducive to achieving standardized and individualized treatment of EAC and EGJA to obtain a better prognosis. This review discusses recent advances in EAC and EGJA treatment in the surgical-centered MDT mode in recent years.

show abstract

Targeted Screening for Barrett’s Esophagus and Esophageal Cancer: Post Hoc Analysis From the Randomized BEST3 Trial

Tan,

Maroni,

Offman

et al. 2024

Gastroenterology

View full text Add to dashboard Cite

Receipt of Serial Endoscopy Procedures Prior to Esophageal Adenocarcinoma Diagnosis Is Associated with Better Survival

Cited by 3 publications

References 20 publications

Management of nondysplastic Barrett’s esophagus: When to survey? When to ablate?

Management of nondysplastic Barrett’s esophagus: When to survey? When to ablate?

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction

Targeted Screening for Barrett’s Esophagus and Esophageal Cancer: Post Hoc Analysis From the Randomized BEST3 Trial

Contact Info

Product

Resources

About